肠促胰岛素
二肽基肽酶
胰高血糖素样肽-1
二肽基肽酶-4
受体
医学
胰高血糖素
艾塞那肽
药理学
内科学
内分泌学
糖尿病
生物
2型糖尿病
生物化学
胰岛素
酶
作者
Vasilis Tsimihodimos,Moses Elisaf
标识
DOI:10.1016/j.ejphar.2017.10.049
摘要
Glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors (collectively termed incretin-based therapies) represent two of the most widely used classes of antidiabetic drugs. These compounds exert their beneficial effects on carbohydrate metabolism through the activation of specific glucagon like peptide-1 receptors in various organs. Accumulating evidence suggests that glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors also affect renal function in both glucagon like peptide-1 receptor-dependent and independent manner. However, the clinical significance of these observations remains indeterminate. In this review, we summarize the available preclinical and clinical data on the effects of incretin-based therapies on renal function indices and discuss their relevance in everyday clinical practise.
科研通智能强力驱动
Strongly Powered by AbleSci AI